Genus begins tumour drug trial
Genus Oncology has also filed an investigational new drug (IND) application with the US Food & Drug Administration (FDA). The prospective, open-label Phase I trial is designed to
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
The randomised, placebo-controlled, multi-centre study was conducted by Glenmark Pharmaceuticals, the partner of Napo Pharmaceuticals. The study results showed that patients receiving crofelemer had significantly higher resolution of